Φορτώνει......
Clinical Considerations for the Pharmacologic Management of Patent Ductus Arteriosus with Cyclooxygenase Inhibitors in Premature Infants
When medical management is warranted for closure of a persistent patent ductus arteriosus (PDA) in premature infants, treatment with a cyclooxygenase (COX) inhibitor is indicated. Indomethacin, available since 1976, has been the conventional pharmacologic treatment for PDA, but its use is associated...
Αποθηκεύτηκε σε:
Κύριοι συγγραφείς: | , |
---|---|
Μορφή: | Artigo |
Γλώσσα: | Inglês |
Έκδοση: |
Pediatric Pharmacy Advocacy Group
2007
|
Θέματα: | |
Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3462097/ https://ncbi.nlm.nih.gov/pubmed/23055850 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5863/1551-6776-12.3.147 |
Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|